TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07114874: A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia

Sponsor: Neurocrine Biosciences · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$14,931,016

Rescue Site Savings

+$9,862,184

Unlock Full NCT07114874 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07114874 Rescue Dossier →